Phase 4 N=22 EMERALD (Emergency Medicine Cardiovascular Risk Assessment for Lipid Disorders)
Lipid Disorder
Primary: Low-density Lipoprotein Cholesterol (LDL-C) Levels at Baseline and Day 30 — 110; 84.0 mg/dL
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=602 Early Risk Stratification in ED Chest Pain Patients
Acute Coronary Syndrome
Primary: Number of Patients With Major Adverse Cardiac Event — 42; 0; 437; 123 Participants
N/A N=871 Risk Markers in the Acute Coronary Syndromes
Chest Pain · Coronary Artery Disease · Unstable Angina Pectoris
Primary: Total Mortality. — 138 Participants.
N/A N=20 Evaluate Cardiac Function Using Cardiac MRI and Dosimetric Correlation
Node Positive Breast Cancer
Primary: Cardiac MRI Parameters — 0; 0; 0; 0 number of patients
N/A N=1,748 Rapid Assessment of Potential Ischaemic Heart Disease With CTCA
Acute Coronary Syndrome
Primary: All-cause Death or Subsequent Non-fatal Type 1 or Type 4b MI at One Year Measured as Time to First Such Event. — 51; 53 Participants
N/A N=523 Risk Stratification in Patients With Preserved Ejection Fraction
Myocardial Infarction
Primary: Number of Participants With Major Arrhythmic Events (MAEs) - Present When One of the Following Occurred: Sudden Cardiac Death, Sustained Ventricular Tachycardia, or…
N/A N=193 Cardiac CT's Role in Asymptomatic Patients With Diabetes and Metabolic Syndrome
Diabetes · Metabolic Syndrome
Primary: Systolic BP Pressure — 145; 144 mm Hg
Phase 1 N=68 Risk-Guided Cardioprotection With Carvedilol in Breast Cancer Patients Treated With Doxorubicin and/or Trastuzumab
Cardiotoxicity · Risk Factor, Cardiovascular · Toxicity Due to Chemotherapy
Primary: Left Ventricular Ejection Fraction (LVEF) — 61.1; 59.0; 61.9; 58.4 percent
N/A N=3,889 Improve Sudden Cardiac Arrest Study
Sudden Cardiac Arrest · Ventricular Arrythmia
Primary: Time to the First Occurrence of a Ventricular Arrhythmia — 32.5; 18.3 Estimated 24-Month VT-VF Pct of Patients
N/A N=200 Novel Biomarkers of Thrombotic Risk
Myocardial Infarction
Primary: Cardiovascular Event - Myocardial Infarction, Stroke, Death — 17; 6 Participants — p=0.007
N/A N=9,559 Treatment of High and Very High riSk Dyslipidemic pAtients for the PreveNTion of CardiOvasculaR Events
Dyslipidemia · Cardiovascular Diseases · Hypercholesterolemia
Primary: Mean Low Density Lipid-Cholesterol (LDL-C) Levels in High and Very High Risk Cardiovascular Participants — 2.40; 1.99 mmol/L
Phase 3 N=600 Cardiovascular Safety of Xenon in General Anaesthesia, in Patient With Cardiovascular Risk in Non Cardiac Surgery
Elevated Cardiac Risk · Coronary Arteries Disease Risk
Primary: Number of Participants With Myocardial Necrosis (MN) — 57; 54 participants — p=0.0052
Phase 3 N=27,564 Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
Dyslipidemia
Primary: Time to Cardiovascular Death, Myocardial Infarction, Hospitalization for Unstable Angina, Stroke, or Coronary Revascularization — 3.11; 2.74; 6.01; 5.31 percentage of…
N/A N=144 Coronary Artery Disease Screening in Kidney Transplant Candidates
End Stage Renal Disease · Coronary Artery Disease
Primary: Number of Participants Adhering to the Expected Number of Screening Tests — 59; 71 participants
Phase 2 N=101 Efficacy of Coreg CR and Lisinopril on Markers for Cardiovascular Functional and Structural Disease
Pre-hypertension
Primary: Change in Disease Score (DS) Among the Treatment Groups — -2.48; -2.29; -2.38; -0.96 Overall Rasmussen Disease Score Change
N/A N=24 Characterizing Chemo-Radiotherapy Treatment-Related Cardiac Changes
Clinical Stage 0 Esophageal Adenocarcinoma AJCC v8 · Clinical Stage 0 Esophageal Squamous Cell Carcinoma AJCC v8 · Clinical Stage I Esophageal Adenocarcinoma AJCC v8
Primary: Proportion of Participants With a Cardiac Event at 12 Months — 0.6818 proportion of participants
N/A N=143 SomaSignal Tests on Medical Management and Change in Risk in Patients With Diabetes
Diabetes Mellitus, Type 2
Primary: Number of Participants With Type 2 Diabetes (T2D) Who Had Prescription Changes in Concordance With SSCVD Results — 45; 13; 8; 35 Participants
N/A N=8 Continuous Cardiac Arrhythmia Monitoring in Hemodialysis Patients
Arrhythmias, Cardiac
Primary: Number of Participants With a Significant Arrhythmia Detected — 0 participants
N/A N=115 Effects of Cardiac Rehabilitation (CR) on Functional Capacity and Cardiovascular Risk Factors
Cardiovascular Disease · Coronary Disease
Primary: Functional Capacity Assessed by Changes in Total Distance Walked in the Incremental Shuttle Walk Test — 488.1; 464.8; 394.0 meters
Phase 3 N=5,035 Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk Open-label Extension
Dyslipidemia
Primary: Number of Participants Who Experienced an Adverse Event — 2144; 2084 Participants
Phase 3 N=103 Multi-Targeted Cardiac Risk Intervention in Type 2 Diabetes
Diabetes · Hypertension · Dyslipidemia
Primary: Percent of Patients Achieving Hemoglobin A1C Goal, LDL Cholesterol Goal, and Systolic Blood Pressure Goal From the Enrollment Until the End of the Study — 40.8; 20.4…
N/A N=202 Impact of a Corrie Cardiac Rehabilitation Program
Coronary Artery Disease · Myocardial Infarction · Myocardial Ischemia
Primary: 6-minute Walking Distance (Meters) — 506.1; 489.8 meters — p=0.04
Phase 2 N=8 Healthy Heart Habits
Acute Coronary Syndrome · Depression
Primary: Acceptability Measured by the Client Satisfaction Questionnaire — 30.57 score on a scale
Phase 2 N=31 Cardiac Safety Study in Patients With HER2 + Breast Cancer
HER2 Positive Breast Cancer · Left Ventricular Function Systolic Dysfunction
Primary: Percentage of Patients Who Complete Planned Oncologic Therapy Without the Development of a Cardiac Event or Asymptomatic Worsening of Cardiac Function. — 27 Participants
N/A N=312 CARISMA : Cardiac Arrhythmias and Risk Stratification After MyoCardial Infarction
Acute Myocardial Infarction
Primary: ECG-documented Ventricular Fibrillation or Symptomatic Sustained Ventricular Tachycardia (VT) — 25; 8; 3; 2 participants
N/A N=40 Long-term Cardiac Monitoring After Cryptogenic Stroke (CMACS)
Stroke
Primary: Completion of Clinical Follow-up as a Measure of Feasibility — 20; 18 participants
N/A N=65,406 Cardiovascular Events in Chronic Obstructive Pulmonary Disease Patients Initiating Olodaterol or Other Long-acting beta2 Agonists
Pulmonary Disease, Chronic Obstructive
Primary: Occurrence of First Hospitalisation or Hospital Outpatient Clinic Visit for Atrial Fibrillation or Flutter (AF) — 246; 725 Events
N/A N=1,392 Computed Tomography Coronary Angiogram (CTCA) Versus Traditional Care in Emergency Department Assessment of Potential Acute Coronary Syndromes (ACS)
Chest Pain · Acute Coronary Syndrome · Acute Myocardial Infarction
Primary: Rates of Major Cardiac Events (AMI or Cardiac Death) Within 30 Days — 0; 0; 0; 10 Participants
N/A N=982 ARgentinean Risk Assessment Registry in ACS; the ARRA-RACS Study
Chest Pain · Coronary Artery Disease · Unstable Angina Pectoris
Primary: Total Mortality. — 173 participants
Phase 4 N=366 A Study of Stress Echocardiography in Post-Menopausal Women at Risk for Coronary Disease
Coronary Artery Disease · Heart Disease
Primary: Number of Participants With Abnormal Contrast Stress Echocardiography and With Future Major Adverse Cardiac Events (MACE) at 2 and 5 Years Follow-Up — 2; 1; 1; 5…